Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

After Rajasthan and Hyderabad, Chhattisgarh today reported three suspected cases of Ebola involving foreign nationals.

According to media reports, the three have been isolated in Durg and placed under a 21-day quarantine as a precaution.

Chhattisgarh Health Minister Shyam Bihari Jaiswal announced that the state is fully prepared to handle any potential Ebola virus infection, stressing that hospitals and quarantine facilities have been put on alert and necessary arrangements are in place to ensure public safety.

Speaking to reporters, Jaiswal said the three individuals under observation were nationals from African countries and were being monitored in line with health protocols.

He added that no Ebola infection had been confirmed so far and that none of the individuals were showing symptoms of the disease.

"We have been fully prepared across the state at every level for a month now. The three individuals placed in isolation in Durg are nationals from African countries and have been quarantined for 21 days as a precautionary measure. So far, tests have not confirmed the presence of the virus, nor are they exhibiting any symptoms," he said.

Two Suspected Cases In Hyderabad

Earlier, two people in Hyderabad who returned from Sudan were isolated.

A Sudanese national, a student in his 20s, with a fever, was admitted to the state-run Gandhi Hospital. The student's condition improved, and he had no fever on Friday morning. His attendant was advised to stay in isolation at home, according to media reports.

Also read: WHO Says Ebola Fight Is Catching Up; Expert Explains Science Behind Patient Recoveries

Another Sudanese national, who arrived at Rajiv Gandhi International Airport a day earlier, was also shifted to the isolation ward of Gandhi Hospital for further tests after he was found to have a fever during thermal screening at the airport. The 35-year-old, who had come to Hyderabad for knee surgery, had no fever as of Friday morning and was asymptomatic, officials said.

Samples containing oral and nasal swabs have been collected and will be sent to the Centre for Cellular and Molecular Biology (CCMB) for testing. Test reports of both individuals are awaited.

Rajasthan Woman Isolated

Meanwhile, Rajasthan has also isolated one woman who returned from Uganda following symptoms.

During routine health screening at the airport, she exhibited symptoms associated with Ebola infection. The health department was immediately informed, and she was placed under special observation.

While she has displayed symptoms similar to Ebola infection, confirmation can only be made after laboratory testing. The results are awaited.

No Ebola Case Reported In India

Read More: Bundibugyo Ebola Outbreak: WHO Identifies Experimental Treatments, Vaccines

All suspected cases have been linked to travel to Ebola-affected countries such as Uganda, the Democratic Republic of Congo, and Sudan.

"No Ebola disease cases have been reported in India," the Health Ministry said in its latest update on June 3. The Health Ministry has also advised travelers arriving from Ebola-affected countries, including Uganda and the Democratic Republic of Congo, to remain alert for symptoms and seek medical guidance if they feel unwell.

"For information, guidance, and assistance, call MoHFW's 24x7 Health Helpline: 1075," the ministry said on X.

Ebola: A Global Health Emergency

On May 17, the World Health Organization classified the Ebola outbreaks in Uganda and the Democratic Republic of Congo as a Public Health Emergency of International Concern (PHEIC).

A total of 452 Ebola cases have been confirmed in the Democratic Republic of Congo, including 82 deaths. Uganda has reported 16 confirmed cases.

Meanwhile, the number of suspected cases has fallen from more than 1,000 last week to 116 as health teams work through the backlog. Six people in the DRC and two in Uganda have recovered to date.

After previously warning that Ebola was "outpacing us," WHO Director-General Tedros Adhanom Ghebreyesus said on Thursday that "we are catching up" as efforts to contain the outbreak in the Democratic Republic of Congo show progress.

A total of 452 Ebola cases have been confirmed in the Democratic Republic of Congo, including 82 deaths. Uganda has reported 16 confirmed cases. Meanwhile, the number of suspected cases has fallen from more than 1,000 last week to 116 as health teams work through the backlog.

WHO Sees Signs of Progress

“What I saw gave me hope,” Ghebreyesus said at a press conference.

“The outbreak had a big head start, and we're still behind, but under the leadership of the Government of DRC, we are catching up,” he added.

Importantly, he noted that six people in the DRC and two in Uganda have recovered to date, “showing that people can survive Ebola if they have access to care and go to health facilities as soon as they show symptoms.”

Why Are Patients Recovering?

The latest outbreak is caused by the Bundibugyo strain of the Ebola virus, for which there is currently neither a vaccine nor an antiviral treatment. So how are patients recovering?

Dr. Rajeev Jayadevan, Co-Chairman of the National IMA COVID Task Force and Past President of the Indian Medical Association, Cochin, told HealthandMe that a combination of factors—including the virus strain, access to medical care, and individual immune responses—can significantly influence whether a patient survives the disease.

Ebola virus disease is a severe illness caused by different strains of the Ebola virus. The current outbreak is linked to the Bundibugyo strain, which has a lower mortality rate than the more lethal Zaire strain responsible for several previous outbreaks, he said.

“The mortality of Ebola virus disease is tied to several components,” Dr. Rajeev explained.

Early Medical Care Improves Survival

One of the most important factors is access to early medical attention and supportive care. Patients who receive prompt treatment at well-equipped healthcare facilities staffed by experienced healthcare workers have a much greater chance of survival.

However, such healthcare access is often limited in outbreak-affected regions of Africa due to ongoing conflicts and socioeconomic challenges.

“The chance of survival is much higher if a person receives good medical attention and early supportive care,” he said.

Bundibugyo Strain vs Zaire Strain

Also read: Ebola Bundibugyo Strain: All You Should Know About The Rare Virus

The strain of the virus also plays a critical role. Dr. Rajeev said that because the Bundibugyo strain is less lethal than the Zaire strain, more infected individuals are expected to survive under similar conditions.

“If a hundred people get infected with the Zaire strain and another hundred with the Bundibugyo strain, more people in the Bundibugyo group will survive, all other conditions remaining the same,” he said.

Difference In Immune Response

Another important factor is the body's immune response, which varies from person to person. Dr. Rajeev highlighted the role of human leukocyte antigens (HLA), proteins that help the immune system recognize and respond to invading pathogens. Because each individual's HLA profile is unique, people infected with the same virus can generate different immune responses.

“HLA works closely with the immune system by presenting pieces of the virus to immune cells, helping the body build a targeted response,” he said.

Also read: Ebola Alert In India: Rajasthan, Hyderabad Report Suspected Cases of Deadly Virus

This biological diversity is one reason why the same infection can affect individuals differently. It is also considered an evolutionary safeguard that helps prevent a single pathogen from devastating the entire human population.

The Role of Probability

Dr. Rajeev also pointed to a simple statistical reality. “If the mortality rate in the current outbreak is around 30 per cent, that means about 70 per cent of infected individuals are expected to survive,” he said.

According to the expert, survival often results from a combination of favorable factors, including infection with a less lethal strain, timely medical care, a strong immune response, and the overall probability of recovery within a given outbreak.

The UK National Health Service (NHS) has approved the free rollout of a breakthrough ovarian cancer drug, benefiting hundreds of women with hard-to-treat cancer starting today.

Importantly, the US FDA-approved drug is the first new addition to NHS treatment for this group of patients in over 20 years.

The last major NHS treatment introduced for these patients was the rollout of liposomal doxorubicin and paclitaxel in the early 2000s.

The NHS, in a statement, said that the new targeted therapy, mirvetuximab soravtansine, will be offered to patients living with ovarian cancer whose disease has stopped responding to standard (platinum-based) chemotherapy, providing new hope of extra time to live.

Mirvetuximab soravtansine (Elahere) has been developed by AbbVie. The NHS estimates up to 400 patients in England each year could benefit.

“This represents the most significant breakthrough in NHS treatment for these hard-to-treat ovarian cancers in over two decades – and we’re delighted it will now offer hundreds of women much-needed hope of precious extra time with their loved ones,” said Professor Ruth Plummer, NHS national clinical lead for cancer drugs.

How Does The Drug Work?

According to the NHS, the drug combines a ‘homing’ antibody with a cancer-killing medicine, often described by scientists as a ‘biological missile’ or ‘Trojan horse’ therapy.

It works by attaching to ovarian cancer cells that have a protein called folate receptor alpha (FRα) on their surface, before releasing a cancer-killing molecule that destroys the cell from within.

In a major global clinical trial involving eight NHS hospitals, the treatment delayed cancer progression and prolonged survival, with patients living 16.5 months on average compared to 12.8 months with chemotherapy.

Also read: New Pancreatic Cancer Drug Daxaronrasib May Benefit Patients With Lung And Ovarian Tumors Too

Who Can Avail The Drug Through The NHS?

Following a recommendation by the National Institute for Health and Care Excellence (NICE), the treatment will be available for:

• patients with epithelial ovarian cancer,
• peritoneal or fallopian tube cancer that has become resistant to platinum-based chemotherapy
• whose tumors contain the FRα protein targeted by the drug.

The treatment is given intravenously (via a drip) over two to four hours, once every three weeks.

Are There Any Side Effects?

The NHS stated that the drug may also have more tolerable side effects than traditional chemotherapy, as it is aimed more precisely at cancer cells than chemotherapy, which can also harm healthy cells.

Common side effects include:

• Eye problems such as blurred vision or dry eyes
• Tiredness
• Nausea
• Low blood counts

Most side effects are manageable with monitoring and supportive care.

Read More: Alan Brazil Shares Survival Story After Heart Stopped During Liver Transplant

Ovarian Cancer Remains A Major Health Challenge

Ovarian cancer is one of the leading causes of death from gynecological cancer worldwide. In the UK, there are around 7,500 new diagnoses each year.

Standard treatment for ovarian cancer typically involves surgery and chemotherapy, but around 80 per cent of patients with advanced disease relapse, and most eventually develop resistance to chemotherapy.

More than a third of patients (37 per cent) treated with mirvetuximab soravtansine also saw their tumors shrink by at least 30 per cent, compared to 16 per cent of patients receiving chemotherapy in clinical trials.